Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma

• Published in: Oral oncology 2024-09, Vol.156, p.106918, Article 106918
• Main Authors: Zhao, Xueyan, Zhou, Yan, Peng, Gang, Wen, Lu, Hong, Xiaohua, Hu, Yuan, Wu, Bian, Liu, Xixi, Zhang, Zhanjie, Xiao, Guixiang, JingHuang, Ding, Qian, Yang, Chengzhang, Xiong, Xingao, Ma, Hui, Shi, Liangliang, Yang, Jinsong, Wei, Jielin, Qin, You, Wan, Chao, Zhong, Yi, Leng, Yangming, Zhang, Tao, Wu, Gang, MinYao, Jia, Yulin, Zhang, Xiaomeng, Yang, Kunyu
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Female; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - mortality; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - therapy; Head and neck squamous cell carcinoma; Humans; Immunotherapy; Immunotherapy - methods; Male; Middle Aged; Neoadjuvant therapy; Neoadjuvant Therapy - methods; Quality of Life; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - mortality; Squamous Cell Carcinoma of Head and Neck - pathology; Squamous Cell Carcinoma of Head and Neck - therapy; Survival
• ISSN: 1368-8375; 1879-0593; 1879-0593
• DOI: 10.1016/j.oraloncology.2024.106918

•We report the final data of a trial of neoadjuvant chemoimmunotherapy for LA HNSCC.•The overall two-year DFS and OS rates were 90% and 100%, respectively.•Neoadjuvant chemotherapy plus camrelizumab showed an acceptable safety profile. Neoadjuvant chemoimmunotherapy has shown promising results for resectable, locoregionally advanced (LA) head and neck squamous cell carcinoma (L/A HNSCC). We published the first phase II trial of neoadjuvant camrelizumab combined with chemotherapy in resectable, L/A HNSCC, demonstrating it was safe and feasible with favorable pathological complete response (pCR). Here, we report the final analysis results for neoadjuvant chemoimmunotherapy in L/A HNSCC (minimum 2.0 years of follow-up). Three cycles of chemoimmunotherapy were administered before surgery to patients with L/A HNSCC. Two-year disease-free survival (DFS), overall survival (OS) and quality of life (QOL) were reported. The overall two-year DFS and OS rates were 90 % and 100 %, respectively. With a median follow-up of 33.7 months, 9 of 10 (90 %) patients with pCR were alive and disease free. Patients with TNM stage (II/III) or